

Amniotic membrane-based antimicrobial agent

Field of use
Healthcare-Medical Science

**Current state
of technology**
Laboratory tested;
preclinical

Intellectual property
Patent pending,
LU101112

Developed by
University of Ljubljana,
Medical Faculty

Reference
UL20180381012

Contact

Knowledge Transfer
Office

Gabriela Droga Mazovec
Phone: +386 1 241 85 83
E-mail: ipr@uni-lj.si

ppz.uni-lj.si



Background

During the years 2000 and 2015, the use of antibiotics worldwide increased for 65%. Epidemiological studies showed the correlation between the increasing use of antibiotics and the emergence and spreading of bacteria, resistant to antibiotics. The studies show there is a great need for discovery and development of novel antimicrobials.

Description of the Invention

The developed mammalian amniotic membrane homogenate can be used as an antimicrobial agent. The preparation of which runs through a well-determined procedure so that its antibacterial characteristics remain intact.

Main Advantages

Antimicrobial activity of amniotic membrane has been proven against several bacteria, namely *Escherichia coli*, *Staphylococcus aureus*, *Enterobacter sp.*, *Klebsiella pneumoniae*, *Staphylococcus saprophyticus* and others. The preparation procedure is simple and cost-effective and the homogenate presents a high efficacy rate.